Pfizer to Ask for Approval for RSV Vaccine for People as Young as 18
Pfizer on April 9 said it will ask U.S. regulators to approve its respiratory syncytial virus (RSV) vaccine for people as young as 18. The pharmaceutical company said that data from an ongoing phase 3 trial showed the vaccine generated an immune response in people deemed at risk of developing severe illness associated with RSV, […]
Read More

